-Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

Media coverage

• Title	-Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
  Media name/outlet	M2 PressWIRE
  Country/Territory	United Kingdom
  Date	1/03/22
  Persons	Paula Busse

• Title	-Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
  Media name/outlet	ENP Newswire
  Date	1/03/22
  Persons	Paula Busse